Kim Hyo-Cheol
Department of Radiology, Seoul National University Hospital, Seoul, Korea.
Clin Mol Hepatol. 2017 Jun;23(2):109-114. doi: 10.3350/cmh.2017.0004. Epub 2017 May 10.
Transarterial radioembolization (TARE) with yttrium 90 (Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass and resin microspheres with different physical characteristics. All patients undergoing TARE must be assessed with clinical examination and laboratory tests as well as a thorough angiographic evaluation. TARE is safe and effective in the treatment of unresectable HCC, as it has longer time-to-progression, greater ability to downsize tumors for liver transplantation, less post-embolization syndrome, and shorter hospitalization compared with chemoembolization. TARE can also serve as an alternative to ablation, surgical resection, portal vein embolization, and sorafenib. The utility of TARE continues to expand with new insights in interventional oncology.
钇90（Y）经动脉放射性栓塞术（TARE）是一种由介入放射科医生实施的动脉内操作，已开始在韩国用于治疗肝细胞癌（HCC）。有两种可用的TARE产品：具有不同物理特性的玻璃微球和树脂微球。所有接受TARE的患者都必须通过临床检查、实验室检查以及全面的血管造影评估进行评估。TARE在治疗不可切除的HCC方面安全有效，因为与化疗栓塞相比，它具有更长的疾病进展时间、更大的缩小肿瘤以进行肝移植的能力、更少的栓塞后综合征以及更短的住院时间。TARE还可以作为消融、手术切除、门静脉栓塞和索拉非尼的替代方法。随着介入肿瘤学的新见解，TARE的效用不断扩大。
